Saturday, 20 October 2018
Intra-tumoural injections- poster discussions
1. SD101- Tol9 receptor agonist plus PD1 in - not sure why you would do that- PD1 naive patients
data for PDL1 status needs to be verified as inconsistent
Interesting bit in here is that seems that the higher dose works less well than the lower dose
2. TLR9-agonister (Tilosotolimod) IMO-2125 plus Ipi in PD1 refractory patients, so the ones who failed PD1 treatment
response in injected and also in un-injected lesions
look into which T-cells clones expanded
3. T-Vec in IIIB-IVM1c patients
biopsies at baseline and day1 of week 6- looking at CD8+ density
no correlate between density and objective response but durable response (objective response >6 months)
change in density didn't correlate with either
but- they change of CD8+ was seen also in uninjected lesions, so there IS a systemic effect of the T-Vec
4. Pembro plus Dab/Tram intermittendly- IMPEMBRA
small numbers, so caution
Hardly novel trial reasoning- better responses early on targeted therapy than on immune therapy- but different lengths of treatment with Dab/Tram
but seems that the Dab/Tram combination creates a favourable environment for immune therapy READ UP
Fake News and Pseudoscience are dangerous for patients. So very pleased and incredibly proud to see Gilly's session covered on the ...
Why treating early stage patients? Early stage patients have all the favourable disease outcomes that we know from Stage 4 cancer immu...
Also this year- updates from ESMO! The program is available online here
Rotterdam criteria Again- tumorload below 0.1 equals no tumour load in the sentinel node in Stage 3A- check out the Rotterdam criteria ...